Stock Info Nets

Independent Financial Information Made Easy

Our AI creates

The Best Stock Graphs and Charts

Youtube Subscribe Blog GamificArt

The development of Artificial Intelligence (AI) is modifying the way investments are evaluated. We programmed an artificial intelligence (A.I.) to summarize the whole internet. Whether you’re trying to make money investing online, making financial decisions or just getting informed about Wall Street, this page is a way to get informed without reading hundred of pages. Our stock market summary graphs are produced using machine learning, an unbiased view to capture what internet is saying. Usually, the AI reads several hundred pages and summarize it to a short text and several charts.

General Description

Protagonist Therapeutics

Youtube Subscribe

...

Ticker: PTGX

Sector: Biotechnology

Protagonist Therapeutics, Inc. develops peptide-based drugs for hematology and blood disorders. Rusfertide (PTG-300) is in Phase II clinical trials for the treatment of erythrocyt.
...
...
Extended Summary

Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Related Results

...
February 05, 2024 23:59 (London Time)

Protagonist Therapeutics

Protagonist Therapeutics shares rise 5.6% on licensing deal with takeda. Japanese pharmas financial numbers showed a drop in operating revenue. Take…
Sector: Biotechnology
Ticker: PTGX
Sentiment: 0.5574
MarketCap: 1,527,893,451.0
High: 26.56 Low: 25.63

Open: 26.0 Close: 26.01 Change: 0.01

Read more →
...
October 18, 2023 21:53 (London Time)

Protagonist Therapeutics

Protagonist Therapeutics, Inc. (PTGX) shares bought by teacher retirement system of texas - defense world. (NASDAQ:PTGx) Shares Bought by Teacher Re…
Sector: Biotechnology
Ticker: PTGX
Sentiment: 0.9001
MarketCap: 891,143,448.0
High: 15.38 Low: 14.78

Open: 15.38 Close: 14.86 Change: -0.52

Read more →
...
November 10, 2023 15:39 (London Time)

Protagonist Therapeutics

Mackenzie Financial Corp lessened its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Mackenzie financial Corp. St…
Sector: Biotechnology
Ticker: PTGX
Sentiment: 0.9403
MarketCap: 867,478,954.0
High: 15.23 Low: 14.78

Open: 15.05 Close: 15.04 Change: -0.01

Read more →
...
May 14, 2023 16:22 (London Time)

Protagonist Therapeutics

Wall Street analysts expect a potential upside of 322.3% in Protagonist Therapeutics (PTGX) The consensus price target hints at a 301.5% upside pote…
Sector: Biotechnology
Ticker: PTGX
Sentiment: 0.9354
MarketCap: 1,396,186,868.0
High: 25.38 Low: 24.58

Open: 24.97 Close: 25.37 Change: 0.4

Read more →
Search
Happening Now
Categories